We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

64 hedge funds and large institutions have $115M invested in UroGen Pharma in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

31,100% more call options, than puts

Call options by funds: $1.25M | Put options by funds: $4K

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

7% more funds holding

Funds holding: 60 → 64 (+4)

4% more capital invested

Capital invested by funds: $111M → $115M (+$4.63M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2.18% less ownership

Funds ownership: 58.58% → 56.4% (-2.2%)

26% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 19

Holders
64
Holders Change
+4
Holders Change %
+6.67%
% of All Funds
1.03%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
10
Increased
14
Reduced
19
Closed
5
Calls
$1.25M
Puts
$4K
Net Calls
+$1.24M
Net Calls Change
+$838K

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$1.71M
2
OM
Opaleye Management
Massachusetts
+$863K
3
Citigroup
Citigroup
New York
+$514K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$369K
5
Citadel Advisors
Citadel Advisors
Florida
+$334K

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$2.97M
2
Millennium Management
Millennium Management
New York
-$1.54M
3
AIM
ARK Investment Management
Florida
-$803K
4
JP Morgan Chase
JP Morgan Chase
New York
-$492K
5
E
Ergoteles
New York
-$406K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$434K +$334K +35,216 +257%
Renaissance Technologies
27
Renaissance Technologies
New York
$384K +$1.89K +200 +0.5%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$346K +$369K +38,972 New
E
29
Ergoteles
New York
$342K -$406K -42,818 -53%
CBA
30
Coastal Bridge Advisors
Connecticut
$328K – – –
GCP
31
GSA Capital Partners
United Kingdom
$275K -$172K -18,176 -37%
BP
32
BBR Partners
New York
$231K – – –
PAI
33
Palo Alto Investors
California
$217K – – –
YAVAPFMC
34
Yahav Achim Ve Achayot - Provident Funds Management Company
Israel
$212K – – –
Goldman Sachs
35
Goldman Sachs
New York
$208K -$1.11K -117 -0.5%
UBS Group
36
UBS Group
Switzerland
$201K -$198K -20,914 -48%
6CM
37
683 Capital Management
New York
$200K +$214K +22,604 New
Northern Trust
38
Northern Trust
Illinois
$194K -$1.68K -177 -0.8%
KHLMTHM
39
Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet
Israel
$183K – – –
Qube Research & Technologies (QRT)
40
Qube Research & Technologies (QRT)
United Kingdom
$150K +$34.1K +3,604 +27%
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$132K +$47 +5 +0%
Barclays
42
Barclays
United Kingdom
$129K +$102K +10,817 +286%
Geode Capital Management
43
Geode Capital Management
Massachusetts
$127K – – –
Man Group
44
Man Group
United Kingdom
$127K +$135K +14,300 New
GC
45
Globeflex Capital
California
$127K +$135K +14,279 New
BFM
46
Boothbay Fund Management
New York
$98.8K +$105K +11,139 New
OC
47
Oppenheimer & Co
New York
$93.2K +$99.5K +10,511 New
EFG
48
Ethos Financial Group
Pennsylvania
$93.1K +$99.4K +10,500 New
Simplex Trading
49
Simplex Trading
Illinois
$29K -$5.16K -545 -14%
Lazard Asset Management
50
Lazard Asset Management
New York
$27K +$29.5K +3,111 New
1
2
3

URGN Hedge Fund Activity: Q4 2022 in Review

64 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2022, worth a combined $115M — up 4.2% from $111M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new URGN positions and 5 closed out — a net gain of 5 holders — while 14 added to existing stakes and 19 trimmed.

The largest buyer was Stonepine Capital Management, adding an estimated $1.71M. The largest seller was Great Point Partners, cutting an estimated $2.97M.

  • 64 institutional investors held UroGen Pharma (URGN) as of Q4 2022, up from 60 in Q3 2022.
  • Funds reported $115M of UroGen Pharma stock for Q4 2022, up 4.2% quarter-over-quarter.
  • 10 funds opened new UroGen Pharma positions in Q4 2022 and 5 closed out, a net change of +5 holders.
  • The largest UroGen Pharma buyer in Q4 2022 was Stonepine Capital Management, an estimated $1.71M added.
  • The largest UroGen Pharma seller in Q4 2022 was Great Point Partners, an estimated $2.97M sold.

Based on aggregated 13F filings for Q4 2022.